Continue with existing partnering model to access those markets, such as COPD and asthma, that require large general sales forces;
Endeavour to maximise the economic return to shareholders, which will involve sharing an increased level of risk in certain indications;
Seek increased economics in the co-development portion of our business model, which also has the important effect of increasing the knowledge base of our employees.
Consider co-promotion or self-commercialisation of certain assets to harness economic returns;
Commercialisation options will be restricted to therapeutic indications which can be addressed by a small, cost-effective and focused sales and marketing infrastructure;
Continue to evaluate the commercial landscape to identify assets and companies that have appropriate infrastructure, as well as meet key financial criteria such as being revenue enhancing and accretive on a cash‑earnings basis.